Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) – Drugs in Development, 2021

According to the recently published report 'Indoleamine 2,3 Dioxygenase 1 – Drugs in Development, 2021'; Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) pipeline Target constitutes close to 38 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes.

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) – Indoleamine-pyrrole 2, 3-dioxygenase 1 is a heme-containing enzyme encoded by the IDO1 gene. This enzyme acts on multiple tryptophan substrates including D-tryptophan, L-tryptophan, 5-hydroxy-tryptophan, tryptamine, and serotonin. This enzyme plays a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation, and antioxidant activity.

The report 'Indoleamine 2,3 Dioxygenase 1 – Drugs in Development, 2021' outlays comprehensive information on the Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 6, 1, 16 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 6 molecules, respectively.

Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Infectious Disease, Metabolic Disorders and Musculoskeletal Disorders which include indications Solid Tumor, Non-Small Cell Lung Cancer, Bladder Cancer, Head And Neck Cancer, Metastatic Melanoma, Colon Cancer, Colorectal Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Lung Cancer, Melanoma, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Ovarian Cancer, Recurrent Glioblastoma Multiforme (GBM), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Adrenal Gland Cancer, Alopecia, Breast Cancer, Cervical Cancer, Colon Carcinoma, Endometrial Cancer, Ependymoma, Gallbladder Cancer, Glioma, Gliosarcoma, Hematological Tumor, High-Grade Glioma, Kaposi Sarcoma, Kidney Cancer (Renal Cell Cancer), Liver Cancer, Medulloblastoma, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Transitional (Urothelial) Tract Cancer, Muscle Invasive Bladder Cancer (MIBC), Nasopharyngeal Cancer, Osteosarcoma, Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Psoriasis, Rectal Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Sarcopenia, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Traumatic Brain Injury, Type 1 Diabetes (Juvenile Diabetes), Ureter Cancer and Urethral Cancer.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)

– The report reviews Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics and enlists all their major and minor projects

– The report assesses Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

BeiGene Ltd

BirchBioMed Inc

Bristol-Myers Squibb Co

CanBas Co Ltd

Chia Tai Tianqing Pharmaceutical Group Co Ltd

Emcure Pharmaceuticals Ltd

F. Hoffmann-La Roche Ltd

Gerologix Inc

Guangzhou BeBetter Medicine Technology Co Ltd

Hutchison MediPharma Ltd

Incyte Corp

IO Biotech ApS

Jiangsu Hengrui Medicine Co Ltd

Kyowa Kirin Co Ltd

Lumos Pharma Inc

Luye Pharma Group Ltd

Merck & Co Inc

Nammi Therapeutics Inc

Netherlands Translational Research Center BV

Orpheris Inc

Phenex Pharmaceuticals AG

Regen BioPharma Inc

Secarna Pharmaceuticals GmbH & Co KG

Shanghai De Novo Pharmatech Co Ltd

Shenzhen Chipscreen Biosciences Co Ltd

Syntekabio Inc

Table of Contents

Table of Contents

Introduction

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Overview

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Therapeutics Development

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Therapeutics Assessment

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Companies Involved in Therapeutics Development

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Drug Profiles

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Dormant Products

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Discontinued Products

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indications, 2021

Number of Products under Development by Indications, 2021 (Contd..1)

Number of Products under Development by Indications, 2021 (Contd..2)

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Companies, 2021 (Contd..3)

Products under Development by Companies, 2021 (Contd..4)

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by BeiGene Ltd, 2021

Pipeline by BirchBioMed Inc, 2021

Pipeline by Bristol-Myers Squibb Co, 2021

Pipeline by CanBas Co Ltd, 2021

Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2021

Pipeline by Emcure Pharmaceuticals Ltd, 2021

Pipeline by F. Hoffmann-La Roche Ltd, 2021

Pipeline by Gerologix Inc, 2021

Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, 2021

Pipeline by Hutchison MediPharma Ltd, 2021

Pipeline by Incyte Corp, 2021

Pipeline by IO Biotech ApS, 2021

Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021

Pipeline by Kyowa Kirin Co Ltd, 2021

Pipeline by Lumos Pharma Inc, 2021

Pipeline by Luye Pharma Group Ltd, 2021

Pipeline by Merck & Co Inc, 2021

Pipeline by Nammi Therapeutics Inc, 2021

Pipeline by Netherlands Translational Research Center BV, 2021

Pipeline by Orpheris Inc, 2021

Pipeline by Phenex Pharmaceuticals AG, 2021

Pipeline by Regen BioPharma Inc, 2021

Pipeline by Secarna Pharmaceuticals GmbH & Co KG, 2021

Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2021

Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2021

Pipeline by Syntekabio Inc, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Dormant Products, 2021 (Contd..2)

Dormant Products, 2021 (Contd..3)

Discontinued Products, 2021

Discontinued Products, 2021 (Contd..1)

Discontinued Products, 2021 (Contd..2)

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports